Conditions: Pulmonary Disease, Chronic Obstructive
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 100
Healthy volunteers: no

Brief summary:
The study is intended to characterize the lung function profile of BI1744 in COPD patients where patients will perform pulmonary function tests at regular intervals for 24 hours at the end of a 6 week treatment period. Each patient will receive all four treatments.

Detailed description:

Arms:
arm 1: Medium Dose once Daily arm 2: Low Dose once Daily arm 3: Placebo once Daily arm 4: 12 mcg twice daily

Interventions: intervention 1: BI 1744 (Olodaterol) Low Dose intervention 2: BI 1744 (Olodaterol) Medium Dose intervention 3: Placebo intervention 4: Foradil
Intervention descriptions: intervention 1: BI1744 Respimat low dose once daily and placebo Foradil intervention 2: BI1744 Respimat medium dose once daily and placebo Foradil intervention 3: Placebo Respimat once daily and placebo Foradil intervention 4: 12 mcg twice daily and placebo Respimat

Protocol document: